- Still's disease is a rare inflammatory condition that can present in both adult and systemic juvenile forms. Treatment primarily focuses on symptom management, inflammation control, and long-term immune modulation using a combination of NSAIDs, corticosteroids, conventional DMARDs, and biologics targeting IL-1 and IL-6 pathways
- The market is witnessing growth due to increased awareness, availability of targeted therapies, and growing access to specialty rheumatology care across emerging markets
- North America holds the largest share in the Still's Disease Treatment market with approximately 40.2%, supported by early diagnosis, clinical research, and access to innovative therapies
- Asia-Pacific is projected to register the highest CAGR due to expanding specialty clinics, greater disease recognition, and increased healthcare investments
- The Anakinra segment is expected to account for the largest market share of 43.1%, due to its widespread clinical use in both adult and pediatric Still’s Disease cases, rapid onset of action, and strong endorsement across treatment guidelines for IL-1 mediated inflammatory disorders
